<DOC>
	<DOC>NCT01774968</DOC>
	<brief_summary>The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.</brief_summary>
	<brief_title>Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Major Have type 2 diabetes mellitus (World Health Organization [WHO] Classification of Diabetes) Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m^2) Have Glycated Hemoglobin A1c (HbA1c) ≥7.5% and ≤12.0%, as measured by the central laboratory at entry Current U100 insulin/analogue users on &gt;200 and ≤600 units per day for ≥3 months at study entry and reconfirmed at randomization Have a history of stable body weight for at least 3 months prior to study entry Concomitant medications may include metformin (MET), dipeptidyl peptidase4 (DPP4) inhibitors approved for use with insulin at time of study entry (for example, sitagliptin, saxagliptin, and linagliptin), pioglitazone, and/or sulfonylureas (SUs)/glinides (repaglinide or nateglinide). Participant's oral antihyperglycemic drug (OAD) dose(s) must have been stable for ≥3 months Major Have type 1 diabetes mellitus or other types of diabetes mellitus apart from type 2 diabetes mellitus Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit of the reference range Have chronic kidney disease stage 4 and higher or history of renal transplantation Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to study entry Have received insulin by continuous subcutaneous insulin infusion in the 3 months prior to study entry Have received U500R in the 3 months prior to study entry Have had a blood transfusion or severe blood loss within 3 months prior to study entry or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia Are taking chronic systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study entry Have an irregular sleep/wake cycle Have used rosiglitazone, once or twicedaily glucagonlike peptide1 (GLP1) receptor agents, pramlintide, or other injectable or oral antihyperglycemic therapy not listed in the inclusion criteria in the 3 months prior to study entry. Participants may not have used onceweekly GLP1 receptor agents in the 4 months prior to study entry Have used any weight loss drugs in the 3 months prior to study entry Have a history of bariatric surgery Have a history of malignancy other than basal cell or squamous cell skin cancer Have New York Heart Association (NYHA) Class III or IV per NYHA Cardiac Disease Functional Classification Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>